文献速递细菌感染、耐药与抗菌药物医院感染防控

肯尼亚落实弗莱明基金:一国卫抗微生物药物耐药监测经验

Fleming Fund Implementation in Kenya: What Have We Learned About Strengthening One Health Antimicrobial Resistance Surveillance for Decision-making?
PubMed 文献 · Clin Infect Dis · 2026-01-01

本文以2018年弗莱明基金实施前为基线,对肯尼亚一国卫抗微生物药物耐药(AMR)监测进行叙述性项目学习总结,梳理治理、实施与政策演变。结果显示监测点从2个人类卫生站点扩至2025年30个人类、动物与环境站点,国家报告整合耐药、抗菌药物消耗与使用数据,世卫组织联合外部评估相关能力由有限提升至已具备。

要点

  • AMR监测由2个人类卫生站点扩展至2025年30个人类、动物与环境站点
  • 国家报告整合AMR、抗菌药物消耗与使用数据,并常规上报全球平台
  • 可持续进展依赖政府主导治理、技术系统与协调伙伴支持及可预测融资

核心结论

  • 肯尼亚经验提示可持续进展依赖将AMR监测嵌入政府主导的治理结构、技术系统与协调的伙伴支持,维持收益需可预测融资与常规数据使用。

研究设计与样本

  • 叙述性项目学习综述,以2018年为弗莱明基金实施前基线,依据国家与全球监测报告、四方机制指标监测框架、治理与政策演变定性证据及弗莱明基金文件。

主要发现

  • 自2018年以来AMR监测从2个人类卫生站点扩展至2025年30个人类、动物与环境站点。
  • 国家报告演变为整合AMR、抗菌药物消耗与抗菌药物使用数据,向全球平台的常规报告趋于成熟。
  • 产出包括仪表板、报告与政策简报,用于指导抗菌药物管理、感染预防与控制、监管行动与政策决策。
  • 外部基准显示AMR相关能力改善,世卫组织联合外部评估在监测与多部门协调方面由有限能力提升至已具备能力。

临床怎么用

  • 可借鉴其以政府主导治理结构整合人类、动物与环境多部门AMR监测并常规利用数据支持决策的做法。

局限性

  • 为叙述性项目学习综述,非系统评价,未报告定量效应值或对照比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Kenya has moved from fragmented, pilot-based antimicrobial resistance (AMR) surveillance toward a coordinated One Health system, and its experience, pathways of change, and remaining gaps are relevant for other low- and middle-income settings working to operationalize One Health AMR surveillance. METHODS: Here, we report a narrative overview of programmatic learning using 2018 as the pre-Fleming Fund baseline, drawing on national and global surveillance reports, monitoring frameworks from the Quadripartite indicators, qualitative evidence on governance, implementation and policy evolution across the One Health sectors, and Fleming Fund documentation. RESULTS: Since 2018, AMR surveillance expanded from 2 human health sites to 30 human, animal, and environmental sites by 2025. National reports evolved to integrate AMR, antimicrobial consumption, and antimicrobial use data; routine reporting to global platforms matured; and outputs such as dashboards, reports, and policy briefs informing stewardship, Infection Prevention and Control, regulatory action, and policy decisions. External benchmarks showed improvement in AMR-related capacity, with World Health Organization Joint External Evaluation scores moving from limited to demonstrated capacity for surveillance and multisectoral coordination. CONCLUSIONS: Kenya's experience suggests that sustainable progress depends on embedding AMR surveillance within government-led governance structures, technical systems, and coordinated partner support, but sustaining gains will require predictable financing and routine data use.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Wesangula E, Gitonga N, Tanui E, et al. Fleming Fund Implementation in Kenya: What Have We Learned About Strengthening One Health Antimicrobial Resistance Surveillance for Decision-making? Clin Infect Dis. 2026. PMID: 42895841. doi:10.1093/cid/ciag500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。